Eikon Therapeutics

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Eikon Therapeutics sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials 6 currently recruiting 4 completed early-phase tilt top decile by trial count

Eikon Therapeutics: 10 sponsored US clinical trials, 6 recruiting.

Eikon Therapeutics sponsors 10 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting, and 4 completed. 0 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Solid Tumors, with 2 trials.

Top-decile sponsor footprint

Eikon Therapeutics ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

10 total, page 1 of 1

RECRUITING Phase 2

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

NCT07365319
RECRUITING Phase 1

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

NCT07262619
RECRUITING Phase 2

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

NCT06697301
RECRUITING Phase 1

A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

NCT06907043
RECRUITING Phase 2

A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC

NCT06246110
RECRUITING Phase 1

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

NCT06253130
COMPLETED Phase 2

BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors

NCT04819373
COMPLETED Phase 1

Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

NCT04840394
COMPLETED Phase 1

BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab

NCT04196530
COMPLETED Phase 1

BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab

NCT03486301

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 4

Therapeutic Areas

Advanced Solid Tumors 2
Mismatch Repair Deficient or MSI-High Solid Tumors 1
MSI-H/dMMR Gastroesophageal-junction Cancer 1
MSI-H/dMMR Colorectal Cancer 1
MSI-H/dMMR Gastric Cancer 1
MSI-H or dMMR Advanced Solid Tumors 1
Advanced Melanoma 1
Tumor, Solid 1
NSCLC 1
Endometrial Cancer 1

What is open in the Eikon Therapeutics pipeline

6 recruiting of 10 indexed (60% open); 4 completed (40%).

Phase mix: 0 late (III/IV) vs 10 early (I/II) (early-phase heavy).

Top condition: Advanced Solid Tumors (2 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Eikon Therapeutics: open-pipeline peers nationwide

Peers matched on 10 registered trials and 60% open enrollment, not the therapeutic-area sidebar.

Eikon Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 4681012 0%20%40%60%80% Total trials Recruiting share Eikon TherapeuticsAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron PharmaceuticalsAlaska Native Tribal Health ConsortiumAnwaar SaeedAutolus LimitedBeam Therapeutics
Eikon Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Eikon Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 trials (± recruiting share)

Sponsors near 60% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Eikon Therapeutics page

10 registered trials is a research-attention snapshot, not an endorsement of Eikon Therapeutics or any single study.

  • 6 of Eikon Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Advanced Solid Tumors is the condition Eikon Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Solid Tumors trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Eikon Therapeutics pipeline card: 10 registered trials from official public datasets.Report a data error.